Australian Advisors Will Ponder Sandoz’ Pegfilgrastim And Pfizer’s Trastuzumab

A body that advises Australia’s Department of Health on reimbursement will in November consider listing applications for Sandoz’ Ziextenzo pegfilgrastim candidate and well as for Pfizer’s recently authorized Trazimera trastuzumab brand.